NASDAQ:OXFD Oxford Immunotec Global (OXFD) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free OXFD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$21.99▼$21.9950-Day Range$21.88▼$21.9952-Week Range$8.37▼$23.11VolumeN/AAverage Volume1.10 million shsMarket Capitalization$570.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Oxford Immunotec Global alerts: Email Address Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Oxford Immunotec Global Stock (NASDAQ:OXFD)Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.Read More Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> OXFD Stock News HeadlinesMarch 18, 2024 | msn.comOxford ranked top city in England for recycling in new government figuresMarch 9, 2024 | msn.comOxford University held training sessions for Chinese doctors accused of harvesting organsMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 2, 2024 | msn.comOxford LTNs: Oxford University research project to mediate debateFebruary 14, 2024 | msn.comOxford Technology Park welcomes engineering services providerFebruary 7, 2024 | cbsnews.comOxford High School shootingFebruary 6, 2024 | cbsnews.comOxford High SchoolJanuary 18, 2024 | msn.comHMV is planning to shake up retail with Oxford Street comebackMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.January 9, 2024 | news.yahoo.comOxford main road reopens as county battles floodsJanuary 5, 2024 | msn.comTechnology firm set for move to Oxford Technology ParkDecember 28, 2023 | msn.comIn demand: How Oxford Street started to get its groove back in 2023November 29, 2023 | msn.comOxford Pride and Oxford University join to commemorate World AIDS DayNovember 26, 2023 | seekingalpha.comOxford Industries: Undervalued Company With Solid BrandNovember 24, 2023 | forbes.comHMV Makes Historic Return To Its Original Oxford Street HomeNovember 14, 2023 | cbsnews.comOxford TownshipSeptember 26, 2023 | msn.comPetrol prices on the rise: Where to find the cheapest fuel in OxfordSeptember 26, 2023 | businesswire.comOxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch ® Prostate Screening Blood Test to Men With Prostate Cancer RiskSeptember 24, 2023 | msn.comLatest milestone for Oxfordshire science park - as Oxford pipped by Cambridge againSeptember 11, 2023 | msn.comBMW announces £600m package for Oxford EV plantAugust 31, 2023 | benzinga.comOxford Science Enterprises Appoints Ed Bussey as Chief Executive OfficerAugust 29, 2023 | msn.comOxford University spinouts venture picks ex-diplomat as new chiefAugust 15, 2023 | benzinga.comOxford Treatment Center at Forefront of Equine-Assisted Therapy Research for AddictionJuly 18, 2023 | benzinga.comOxford Finance Announces the Closing of a $42 Million Credit Facility with Amino HealthJune 8, 2023 | msn.comCitigroup Reiterates Oxford Nanopore Technologies (LON:ONT) Buy RecommendationMay 17, 2023 | marketwatch.comLatent Tuberculosis Infection (LTBI) Testing Market Size: Growth Dynamics from 2023 to 2031May 16, 2023 | marketwatch.com2030, ELISpot and FluoroSpot Assay Market: Growth & StatisticsSee More Headlines Receive OXFD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Immunotec Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:OXFD CUSIPN/A CIK1586049 Webwww.oxfordimmunotec.com Phone44-0-12-3544-2780FaxN/AEmployees273Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,810,000.00 Net Margins-30.51% Pretax MarginN/A Return on Equity-8.39% Return on Assets-7.63% Debt Debt-to-Equity RatioN/A Current Ratio15.96 Quick Ratio14.85 Sales & Book Value Annual Sales$73.71 million Price / Sales7.75 Cash Flow$0.02 per share Price / Cash Flow1,408.78 Book Value$8.08 per share Price / Book2.72Miscellaneous Outstanding Shares25,962,000Free FloatN/AMarket Cap$570.90 million OptionableNot Optionable Beta1.42 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Peter Wrighton-Smith (Age 47)CEO & Exec. Director Comp: $1.11MMr. Matthew T.E. McLaughlin (Age 44)Chief Financial Officer Comp: $527.45kMs. Janet Louise Kidd (Age 51)Gen. Counsel & Company Sec. Dr. Peter Edwardson (Age 59)Sr. VP & Head of Blood Screening Mr. Jeff R. Schroeder (Age 60)Pres, Strategic Accounts Key CompetitorsImmuCellNASDAQ:ICCCAspira Women's HealthNASDAQ:AWHMeridian BioscienceNASDAQ:VIVOMyriad GeneticsNASDAQ:MYGNAlectorNASDAQ:ALECView All Competitors OXFD Stock Analysis - Frequently Asked Questions How were Oxford Immunotec Global's earnings last quarter? Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The firm earned $19.44 million during the quarter, compared to analysts' expectations of $18.58 million. Oxford Immunotec Global had a negative trailing twelve-month return on equity of 8.39% and a negative net margin of 30.51%. What is Peter Wrighton-Smith's approval rating as Oxford Immunotec Global's CEO? 39 employees have rated Oxford Immunotec Global Chief Executive Officer Peter Wrighton-Smith on Glassdoor.com. Peter Wrighton-Smith has an approval rating of 75% among the company's employees. What other stocks do shareholders of Oxford Immunotec Global own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Dynavax Technologies (DVAX), AbbVie (ABBV), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Immunomedics (IMMU), Intel (INTC), Iovance Biotherapeutics (IOVA), Inovio Pharmaceuticals (INO) and Netflix (NFLX). This page (NASDAQ:OXFD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Immunotec Global PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.